PharmacoEconomics and Outcomes News

Gains from the Massachusetts health reforms
pp. 1-1(1)

NHS reforms complicating the push for efficiency gains
pp. 2-2(1)

Chronic illness and disability costs crippling some Australians
pp. 2-2(1)

Reliance on private sector could spell danger for UK's NHS
pp. 2-2(1)

New treatment guidelines for plaque psoriasis in the USA
pp. 2-2(1)

Fully-funded influenza vaccination of elderly worth it in Poland
pp. 3-3(1)

Rivaroxaban better than enoxaparin for post-surgical VTE
pp. 3-3(1)

"Catastrophic" medical costs for diabetics in low-income countries
pp. 3-3(1)

Costs prevent 10% of Canadians from adhering to therapy
pp. 3-3(1)

Cost-effective treatments for colorectal cancer
pp. 4-4(1)

Both primary and booster coverage affected by US Hib vax shortage
pp. 4-4(1)

Best TB diagnostic strategy for patients initiating ART?
pp. 4-4(1)

Double-unit UCBT best for acute leukaemia?
pp. 5-5(1)

Cotrimoxazole cost effective in first 6 months of ART
pp. 5-5(1)

Could broad-spectrum HPV vax reduce the need for screening?
pp. 5-5(1)

Costs of treating chronic hep B vary according to guideline used
pp. 5-5(1)

Pneumonia a "substantial burden" to Australian health system
pp. 6-6(1)

Non-formulary PPI use uncommon but costly in VA population
pp. 6-6(1)

First-line FOLFIRINOX "attractive cost-effective treatment" for mPC
pp. 6-6(1)

Maintenance pemetrexed not cost effective in Switzerland
pp. 6-6(1)

Which cervical cancer screening interval and test is best?
pp. 7-7(1)

Semi-annual surveillance for HCC cost effective in cirrhotic patients?
pp. 7-7(1)

Routine PCV-10 vaccination best choice for Colombian children
pp. 7-7(1)

Effect of increased reimbursement on adolescent vaccine uptake
pp. 8-8(1)

Uterine fibroids a substantial burden to US society
pp. 8-8(1)

G-CSF cost-neutral for early-stage breast cancer
pp. 9-9(1)

Treating hypertension is highly cost effective in Greece
pp. 9-9(1)

Self-monitoring blood glucose costs high for T1DM patients
pp. 9-9(1)

Risk-adaptive use of plerixafor effective and saves costs
pp. 9-9(1)

Israel is to add 77 new treatments to its basket of drugs for reimbursement
pp. 10-10(1)

Poorer tolerance and higher costs after switch to capecitabine
pp. 10-10(1)

Neoadjuvant CRT prior to surgery cost effective for pancreatic cancer
pp. 10-10(1)

NICE gives final guidance on apixaban for VTE
pp. 10-10(1)

Ireland could cut branded drug prices substantially, says report
pp. 10-10(1)

Latest advice from the SMC
pp. 11-11(1)

Globally, the stem cell therapy market is expected to exceed $US700 million, and may even reach over $1 billion given some positive trends
pp. 11-11(1)

Despite steady growth in the number of coronary stenting procedures, the European coronary stent market is set to shrink to $US490 million by 2016
pp. 11-11(1)

Eribulin is now available under national reimbursement in Italy for women with locally advanced or metastatic breast cancer
pp. 11-11(1)